Days after case withdrawn, licence of Medanta’s pharmacy suspended | Gurgaon Information


GURUGRAM: The licence of Medanta’s inside pharmacy was suspended on Thursday by the district drug management officer for “violations” discovered in the course of the medical board’s probe into complaints of overcharging by the daddy of Saurya Pratap, the seven-year-old boy who died final 12 months after a dengue an infection.
The belated step, nevertheless, got here practically a month after the medical board submitted its report on March 5 and nearly per week after Saurya Pratap’s father introduced at a press convention he had accepted full reimbursement of his son’s remedy price (Rs 15.88 lakh) from Medanta and promised in return that he wouldn’t pursue a authorized case towards the hospital.
In line with the probe, the hospital overcharged for medicines and didn’t keep correct payments and information. “We suspended the licence of the interior pharmacy on the hospital after violations had been noticed in Saurya Pratap’s case. The motion has been taken after the hospital didn’t submit an acceptable reply to the discover,” senior drug officer Sunil Chaudhary advised TOI. The hospital didn’t reply to requests for a remark.
In December 2017, the licences of the pharmacy and blood financial institution at Fortis Memorial Analysis Institute (FMRI) had been suspended in the same probe that was initiated on a criticism from the daddy of Adya Singh, one other seven-year-old who succumbed to dengue.
Saurya Pratap was admitted to Medanta on October 30 final 12 months. He was affected by extreme dengue with multi-organ dysfunction syndrome. The boy was shifted to Ram Manohar Lohia Hospital in Delhi on November 20 since there was no enchancment in his situation, and the invoice was working excessive. He was crucial on the time of admission to RML and died on November 22. His father Gopendra, an LIC agent primarily based in Rajasthan’s Dhaulpur district, needed to mortgage his home to pay the remedy price.
The Medanta pharmacy, in line with the probe report, didn’t point out the addresses of the physician and affected person on the meting out sheet or invoice. The payments had been issued by a pharmacist totally different from the registered one and whose title was printed on the bill.
A violation of the Drug Value Management Order 2013 was additionally noticed with respect to the utmost retail worth (MRP) of three injections — heparin, dexamethasone and metronidazole.
These three medication had been bought at a worth increased than the MRP prescribed by Nationwide Pharmaceutical Pricing Authority, in line with the report. Completely different manufacturers of the identical drug with totally different MRPs had been additionally issued, the probe discovered.


Supply hyperlink